ChromaDex Is Maintained at Buy by Roth MKM

ChromaDex Is Maintained at Buy by Roth MKM

Dow JonesApr 9 22:10

Roth MKM: Maintains ChromaDEX (CDXC.US) rating, adjusted from buy to buy rating, and adjusted target price from $4.25 to $6.00.

Roth MKM: Maintains ChromaDEX (CDXC.US) rating, adjusted from buy to buy rating, and adjusted target price from $4.25 to $6.00.

Zhitong FinanceApr 9 22:02

Roth MKM Maintains Buy on ChromaDex, Raises Price Target to $6

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target from $4.25 to $6.

BenzingaApr 9 21:59

Should You Investigate ChromaDex Corporation (NASDAQ:CDXC) At US$4.32?

While ChromaDex Corporation (NASDAQ:CDXC) might not have the largest market cap around , it saw a significant share price rise of 218% in the past couple of months on the NASDAQCM. The company's

Simply Wall StApr 5 18:35

ChromaDex Announces Tru Niagen Is Now Third-Party Verified Through the Alkemist Assured Transparency Program

All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport) are Alkemist Assured ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and

BusinesswireMar 26 20:32

12 Health Care Stocks Moving In Monday's Intraday Session

GainersFresh2 Group (NASDAQ:FRES) shares rose 41.7% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $15.7 million. Akso Health Group (NASDAQ:AHG) stock mov

BenzingaMar 19 01:31